ICON PLC (ICLR) ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Sector: Services-Commercial Physical & Biological Research
Industry: Medical - Diagnostics & Research
ICON Public Limited Company NASDAQ:ICLR Healthcare · Medical - Diagnostics & Research
Mkt Cap $15.83B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ● Major ⚠ 3
ICON Reports Third Quarter 2026 Results
ICON reported Q3 2026 revenue of $2,024.8 million, down 2.9% year-over-year, with GAAP diluted EPS of $1.58 and adjusted diluted EPS of $2.66 versus $3.20 in Q3 2025.
Commercial momentum was strong: gross bookings rose 26.9% YoY to $3,789 million, net business wins were $3,150 million (1.56x book-to-bill), and backlog closed at $24.5 billion, up 4.8% sequentially.
Free cash flow was $302.4 million; the company repurchased $400 million of stock at an average $170 per share and the board raised the buyback authorization to $750 million. An August $2.15 billion investment-grade bond issuance refinanced $2.15 billion of prior debt, leaving net debt at $2.6 billion.
Management updated FY2026 guidance to revenue of $8,100-$8,200 million and adjusted diluted EPS of $10.35-$10.65.
• 5d ago AI analysis › Press Release
ICON Schedules Third Quarter 2026 Earnings Conference Call
ICON plc (NASDAQ: ICLR) will release its third quarter 2026 financial results after the market closes on Tuesday, October 27, 2026.
A conference call and webcast to discuss results and performance will be held Wednesday, October 28, 2026 at 8:00am ET, with a replay available roughly one hour later.
This is a scheduling announcement only; no financial results or guidance are included.
• 24d ago AI analysis › Press Release
ICON Releases 2025 ICON Cares Report, Highlighting Progress in Patient Impact, Innovation and Sustainability
ICON plc released its 2025 ICON Cares ESG report, detailing progress in sustainability, clinical innovation, and governance.
The company achieved an EcoVadis Platinum Medal score of 87/100 and reduced Scope 1 and 2 emissions by 73.56% against a 2019 baseline, surpassing its science-based targets early.
Operationally, ICON supported over 1,370 clinical studies involving more than 411,400 patients, contributing to 25 product approvals, while its AI platform Orbis won Project of the Year.
• 2mo ago AI analysis › Press Release ● Major
ICON Announces Pricing of USD 2.15 Billion Notes
ICON priced $2.15 billion of senior unsecured notes across three tranches, extending maturities to 2029, 2031, and 2036 with coupon rates ranging from 5.064% to 5.995%.
Net proceeds will fully repay the bridge facility and existing term loans, and redeem the 2027 Senior Secured Notes, effectively pushing out the debt wall.
This refinancing will also automatically release collateral backing the revolving credit facility and existing subsidiary guarantees, enhancing liquidity.
• 2mo ago AI analysis › Press Release
ICON Announces Private Offering of Notes
ICON plc intends to offer senior notes in a private placement to repay its bridge facility, term loans, and redeem 5.809% Senior Secured Notes due 2027.
The transaction is designed to release collateral currently securing the company’s revolving credit facility, thereby enhancing financial flexibility.
The offering is subject to market conditions, and there is no assurance that the transaction will close or that the collateral release will occur.
• 2mo ago AI analysis › Press Release
ICON Announces Results of Annual General Meeting
ICON plc announced the results of its Annual General Meeting held on July 31, 2026, confirming that all proposed resolutions were passed by shareholders.
The voting results included the re-election of directors Ciaran Murray, Rónán Murphy, Dr. John Climax, Ms. Julie O’Neill, Mr. Eugene McCague, Dr. Linda Grais, and Ms. Anne Whitaker, alongside the election of Barry Balfe, Kevin Egan, and Jeff Elliott.
Additionally, shareholders authorized the Company to allot shares, disapply pre-emption rights, and make market purchases of shares, with all votes passing with high levels of support.
• 3mo ago AI analysis › Press Release ⚠ 3
ICON Reports Second Quarter 2026 Results
ICON reported Q2 revenue of $2.06 billion, up 1.2% year-over-year, with GAAP net income of $72.6 million ($0.94 EPS). Adjusted EPS came in at $2.56, down from $3.52 in the prior year, as adjusted EBITDA fell 21.7% to $327.2 million.
Net business wins totaled $3.12 billion for a book-to-bill ratio of 1.51, driving backlog up 3.0% sequentially to $23.4 billion. Free cash flow was strong at $238.9 million, bolstering the balance sheet.
The company reaffirmed its full-year 2026 guidance for revenue of $7.85B to $8.15B and adjusted EPS of $10.00 to $11.00. Management cited disciplined cost management offsetting headwinds as a reason for confidence in the outlook.
• 3mo ago AI analysis › Press Release
ICON announces multi-year collaboration with Anthropic to bring frontier AI to clinical trials
ICON plc formed a multi-year collaboration with Anthropic to integrate Claude's AI capabilities across the clinical trial lifecycle, enhancing its Orbis platform with four new production capabilities.
The initiative targets site intelligence, predictive enrolment risk detection, protocol optimization and ecosystem integration to accelerate study startup and execution.
ICON plans a role-based rollout of Claude tools across its organization to automate repetitive tasks and improve decision-making speed.
• 3mo ago AI analysis › Press Release
ICON Schedules Second Quarter 2026 Earnings Conference Call
ICON plc announced it will release its second quarter 2026 financial results after the market closes on Wednesday, July 29, 2026.
The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, July 30, 2026, at 8:00am ET.
A webcast replay of the conference call will be available approximately one hour following the conclusion of the call.
• 3mo ago AI analysis › Press Release ⚠ 3
ICON Reports First Quarter 2026 Results
ICON reported Q1 2026 revenue of $2.03 billion, up 0.9% year-over-year, with adjusted EPS of $2.50, down from $3.27 in the prior year. Adjusted EBITDA decreased 20.2% to $317.7 million, while GAAP net income was $104.8 million.
Operational metrics showed strength with net business wins of $2.88 billion, a net book-to-bill of 1.42, and backlog increasing 4.0% to $22.7 billion.
The company reaffirmed its 2026 full-year financial guidance, expecting revenue in the range of $7.85 billion to $8.15 billion and adjusted diluted EPS between $10.00 and $11.00.
• 4mo ago AI analysis › Press Release
ICON selects Microsoft as a preferred technology partner to power AI-enabled clinical development
ICON announced a strategic partnership with Microsoft to advance its AI and digital innovation strategy over the next three years.
The collaboration involves an enterprise-wide deployment of Microsoft 365 Copilot and the use of Azure and Microsoft Fabric to scale ICON's proprietary Orbis AI platform.
CEO Barry Balfe stated that this move positions ICON at the forefront of the transition to AI-enabled clinical trials, aiming to improve productivity and decision-making across the lifecycle.
• 4mo ago AI analysis › Press Release
ICON Schedules First Quarter 2026 Earnings Conference Call
ICON plc announced it will release its financial results for the first quarter of 2026 after the market closes on Tuesday, June 23, 2026.
The company scheduled a conference call and webcast to discuss these results for Wednesday, June 24, 2026 at 8:00am ET, with a webcast replay available one hour later.
ICON is a world-leading clinical research organization employing approximately 40,100 people across 55 countries as of December 31, 2025.
• 4mo ago AI analysis › Press Release ● Major ⚠ 4
ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation
ICON plc reported Q4 2025 revenue of $2.11 billion and full-year revenue of $8.25 billion, with adjusted diluted EPS of $12.53 for the year, slightly below the prior year's $13.37.
The company issued FY26 guidance for revenue between $7.85 billion and $8.15 billion and adjusted diluted EPS between $10.00 and $11.00, reflecting a continued deceleration in growth.
Critically, ICON announced the conclusion of an Audit Committee investigation into accounting practices, revealing material weaknesses in internal controls and requiring a restatement of 2023 and 2024 financials due to revenue overstatements of $65.3 million and $92.7 million, respectively.
The company also appointed Kevin Egan and Jeff Elliott to its Board of Directors to strengthen financial oversight, while Steve Cutler resigned.
• 5mo ago AI analysis › Press Release ⚠ 3
ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq
ICON plc received a written deficiency notice from Nasdaq for failing to timely file its Annual Report on Form 20-F for the year ended December 31, 2025.
The company has 60 calendar days to submit a plan to regain compliance, though it expects to file the Form 20-F in advance of its earnings conference call on May 28, 2026.
ICON will release its fourth quarter and full year 2025 financial results after market close on May 27, 2026.
• 5mo ago AI analysis › Press Release
ICON expands US early phase research capabilities with new clinic and outpatient centres
businesswire.com • 5mo ago Press Release ● Critical
HealthVerity to Acquire Symphony Health, Uniting Clinical Data and Commercial Analytics to Accelerate Breakthroughs Across the Healthcare Ecosystem
globenewswire.com • 5mo ago Press Release ● Major
ICON Provides Update on Audit Committee Investigation and Timing of Fourth Quarter and Full Year 2025 Financial Results
businesswire.com • 6mo ago Press Release ● Major
ICON and Advarra Introduce New ‘Research-Ready,' Connected Site Network Model
businesswire.com • 7mo ago 
